[Chemotherapy of cancer of the breast in the metastatic phase].
Metastatic breast adenocarcinoma is a very chemosensitive tumor. Polychemotherapy (CT) is more active than mono-CT inducing a 50-60% response rate in naive chemotherapy patients. The response rate is increased by adding hormonotherapy (HT) to CT in hormone-receptors positive patients. Whether or not HT and CT should be concomitant or consecutive is still questionable. The overall survival remains poor (22-30 months) and no improvement happened during the last decades. A hope for the future is possible from 2 different concepts: high dose chemotherapy or intermittent CT with successive short inductions treatment and no maintenance therapy.
Clavel
M
M
Centre Léon-Bérard, Lyon, France.
Biron
P
P
Chauvin
F
F
Guastalla
J P
JP
Rebattu
P
P
el Foudeh
M
M
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D012739:Gonadal Steroid Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D009362:Neoplasm Metastasis
D012739:Gonadal Steroid Hormones
La chimiothérapie du cancer du sein en phase métastatique.